Axiom Advisory LLC Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

Axiom Advisory LLC boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,672 shares of the company’s stock after purchasing an additional 198 shares during the quarter. Axiom Advisory LLC’s holdings in Moderna were worth $847,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after buying an additional 5,129,800 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares during the last quarter. Capital World Investors raised its position in shares of Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Mawer Investment Management Ltd. boosted its stake in Moderna by 6.7% in the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after purchasing an additional 120,621 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after purchasing an additional 463,960 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of Moderna stock opened at $58.39 on Wednesday. The stock has a market cap of $22.38 billion, a P/E ratio of -3.73 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock’s fifty day moving average is $75.97 and its 200 day moving average is $107.38. Moderna, Inc. has a one year low of $57.75 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the business posted ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% on a year-over-year basis. Sell-side analysts anticipate that Moderna, Inc. will post -9.86 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the transaction, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,184 shares of company stock valued at $7,464,331. 15.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on MRNA shares. Bank of America decreased their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Barclays decreased their price target on Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research note on Monday, September 16th. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Finally, Jefferies Financial Group lowered Moderna from a “buy” rating to a “hold” rating and decreased their target price for the stock from $120.00 to $65.00 in a research report on Friday, September 13th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $100.44.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.